Mohit Anand, MD
Internal Medicine · Locust Grove, VANPI 1912976077
Payments from drug & device makers
Across 127 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$374
- Novo Nordisk$281
- AbbVie$267
- AstraZeneca$247
- Amarin Pharma, Inc.$143
- Esperion Therapeutics, Inc.$115
- plus $866 from 25 others
What the payments were for
- Food & beverage$2,28099%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $374 |
| Novo Nordisk | 17 | $281 |
| AbbVie(2 entities) | 12 | $267 |
| AstraZeneca(2 entities) | 13 | $247 |
| Amarin Pharma, Inc. | 8 | $143 |
| Esperion Therapeutics, Inc. | 5 | $115 |
| Sunovion Pharmaceuticals Inc. | 5 | $101 |
| Merck | 8 | $98 |
| Pfizer | 6 | $93 |
| Novartis | 4 | $58 |
| Boehringer Ingelheim | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Johnson & Johnson | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Neurelis, Inc. | 2 | $31 |
| GSK | 1 | $29 |
| Astellas Pharma US Inc | 1 | $24 |
| SK Life Science, Inc. | 1 | $23 |
| Cranial Technologies, Inc | 1 | $22 |
| Abbott | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Vyera Pharmaceuticals, LLC | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $14 |
| Bayer | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Clarus Therapeutics Inc. | 1 | $11 |
How this compares
$2,293 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $88,872 |
| OzempicSemaglutide | 44 | $55,150 |
| JardianceEmpagliflozin | 30 | $50,434 |
| TrulicityDulaglutide | 33 | $42,095 |
| JanuviaSitagliptin Phosphate | 25 | $38,900 |
| MounjaroTirzepatide | 29 | $29,464 |
| FarxigaDapagliflozin Propanediol | 14 | $22,998 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $18,355 |
| XareltoRivaroxaban | 14 | $14,284 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $12,683 |
| MyrbetriqMirabegron | 16 | $11,536 |
| BrilintaTicagrelor | 14 | $10,604 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $9,755 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $8,727 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $7,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $93 | $88,87278 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $31 | $71,55862 claims |
| MerckJanuvia, Janumet | $98 | $57,25536 claims |
| Novo NordiskOzempic | $281 | $55,15044 claims |
| Boehringer IngelheimJardiance | $53 | $50,43430 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $247 | $42,32957 claims |
| Johnson & JohnsonXarelto | $38 | $14,28414 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $11,53616 claims |
| GSKAnoro Ellipta | $29 | $5,72511 claims |
| AbbVieSynthroid | $267 | $2,36053 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Locust Grove
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.